Camptotheca acuminata, a deciduous tree native to southern China, produces a chemical compound called camptothecin that became one of the most important anticancer discoveries of the twentieth century. Drugs derived from this single tree species are now standard treatments for colorectal cancer, ovarian cancer, lung cancer, and several other malignancies. The story of how a rare Chinese tree ended up at the center of modern oncology involves decades of setbacks, clever chemistry, and a mechanism of action that researchers did not fully understand until long after the compound was first isolated.
A Tree With an Unlikely Nickname
Camptotheca acuminata goes by several common names, including “happy tree” and “tree of life,” translations that feel almost too on the nose given its medical significance. It belongs to the family Nyssaceae and grows naturally in warm, moist regions of southern China, where it can reach heights of about 20 meters. Wild populations have been declining for decades, and the species is now classified as a key protected species in China with dwindling wild resources.1PubMed Central. Insight into the Influence of Ecological Factors on Shaping Distribution Patterns of Camptotheca acuminata for Conservation and Management Experimental plantations exist outside China, but the genetic diversity of cultivated trees is extremely narrow, which poses its own risks for long-term supply.2HortScience. Micropropagation of Camptotheca acuminata
How Camptothecin Was Discovered
The compound’s discovery traces back to the 1950s and 1960s, when the U.S. Department of Agriculture systematically collected plant samples from around the world and screened them for biological activity. Monroe E. Wall and Mansukh C. Wani, working at the Research Triangle Institute in North Carolina, isolated camptothecin from Camptotheca acuminata and identified it as a potent killer of cancer cells.3PubMed. Camptothecin and taxol: historic achievements in natural products research Wall and Wani would later go on to discover paclitaxel (Taxol) from the Pacific yew tree, making them responsible for two of the most consequential anticancer compounds ever found in nature. But camptothecin came first, and its path from lab curiosity to approved medicine was far rockier.
How Camptothecin Kills Cancer Cells
Every time a cell divides, it has to unwind its tightly coiled DNA. An enzyme called topoisomerase I handles part of this job by cutting one strand of the DNA double helix, letting it untwist, and then resealing the cut. This is a normal, essential process. Camptothecin works by wedging itself into the spot where topoisomerase I is temporarily attached to the cut DNA strand, preventing the enzyme from resealing the break.4PubMed. Topoisomerase I inhibitors: camptothecins and beyond The drug effectively freezes the enzyme in mid-action.
Structural studies have shown exactly what this looks like at the molecular level. Camptothecin slips between the DNA base pairs at the cleavage site, held in place by a web of chemical interactions with both the enzyme and the DNA itself.5PubMed. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin Crystallography work confirmed that the drug mimics a DNA base pair and intercalates right at the cleavage point.6PubMed Central. The mechanism of topoisomerase I poisoning by a camptothecin analog
A single trapped enzyme-DNA complex is not necessarily lethal to the cell. The real damage happens when the cell tries to copy its DNA during replication. The replication machinery barrels into the trapped complex and converts the single-strand nick into a double-strand break, which is one of the most catastrophic things that can happen to DNA. These double-strand breaks are concentrated in actively replicating DNA and are extremely toxic to the cell.7PubMed. Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells This is why camptothecin is especially deadly to cells that are dividing rapidly, which is exactly what cancer cells do.
Why the Original Compound Failed in the Clinic
If camptothecin is so effective at killing cancer cells, you might wonder why it took decades to become useful medicine. The problem was practical. Camptothecin barely dissolves in water, which made it extremely difficult to administer to patients. Early clinical trials in the 1970s used a sodium salt form that was more soluble but came with severe, unpredictable toxicity and erratic absorption. The results were so discouraging that the compound was shelved for over a decade.8PubMed. Camptothecins: a review of their development and schedules of administration
Interest revived in the 1980s for a few converging reasons. Researchers identified topoisomerase I as camptothecin’s specific cellular target. They also discovered that this enzyme tends to be overexpressed in many cancer types, meaning cancer cells are disproportionately vulnerable. And chemists worked out the structural features of the molecule that mattered most for activity, which opened the door to designing modified versions that kept the cancer-killing ability while fixing the solubility and toxicity problems.8PubMed. Camptothecins: a review of their development and schedules of administration
The Drugs That Made It to Patients
The two most successful offspring of camptothecin are irinotecan and topotecan, both semi-synthetic derivatives engineered to be more water-soluble and better tolerated than the parent compound.
Irinotecan transformed the treatment of metastatic colorectal cancer. It works as a prodrug, meaning the body converts it into its active form, called SN-38, using an enzyme called carboxylesterase. When irinotecan was introduced for colorectal cancer in the late 1990s, survival for patients with advanced disease improved substantially. It is now routinely combined with other chemotherapy agents and molecularly-targeted drugs, pushing overall survival in metastatic colorectal cancer beyond 30 months.9PubMed Central. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Topotecan found its niche in ovarian cancer and small cell lung cancer. It was approved as a specific topoisomerase I inhibitor for patients with refractory ovarian carcinoma.10PubMed. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems In small cell lung cancer, the standard dosing schedule can cause significant drops in white blood cell counts, particularly in patients who have already received other chemotherapy. Weekly dosing schedules were explored in hopes of reducing this toxicity, and preliminary results at lower doses showed some promise.11PubMed. Emerging role of weekly topotecan in recurrent small cell lung cancer However, attempts to push the weekly dose higher proved unfeasible due to blood-related toxicity without improving effectiveness.12PubMed. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer The therapeutic window for these drugs is real but narrow, which is a recurring theme in camptothecin pharmacology.
Why Cancer Cells Become Resistant
One of the frustrations of camptothecin-based therapy is that tumors can develop resistance over time. Several mechanisms are at play. Some cancer cells ramp up production of drug efflux pumps, particularly a protein called P-glycoprotein, which actively pushes the drug out of the cell before it can do damage. Research into how camptothecin analogs interact with P-glycoprotein has shown that different drugs in this class trigger distinct shape changes in the pump protein, which helps explain why some analogs are pumped out more efficiently than others.13PubMed Central. Drug-Induced Conformational Dynamics of P-Glycoprotein Underlies the Transport of Camptothecin Analogs
Other resistance mechanisms affect the drug’s metabolism or its target directly. A particularly striking finding is that cancer cells can eliminate hundreds of thousands of topoisomerase I binding sites on their DNA, essentially removing the places where the drug needs to act. This appears to arise as a consequence of repairing the very DNA damage that the drug initially inflicts, meaning the treatment itself can sow the seeds of resistance.14PubMed Central. Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us
Antibody-Drug Conjugates and the New Wave
Rather than trying to improve camptothecin analogs as standalone drugs, much of the current excitement in the field revolves around using them as warheads in precision-guided delivery systems. Antibody-drug conjugates, or ADCs, attach a potent cell-killing payload to an antibody that homes in on a specific protein found on the surface of cancer cells. The antibody delivers the drug directly to the tumor, sparing healthy tissue from most of the toxicity that made early camptothecin trials so brutal.
Exatecan and its derivative deruxtecan (often written DXd) are camptothecin-based payloads now at the center of this approach. They are being developed in various formulations including ADCs, peptide conjugates, liposomes, and nanoparticle carriers.15PubMed Central. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor ADCs incorporating DXd have shown promising clinical results in solid tumors, and researchers are developing new camptothecin-based ADCs with modified chemical structures that perform comparably in laboratory and animal studies.16PubMed Central. Synthesis and Evaluation of Camptothecin Antibody-Drug Conjugates The crystal structures of camptothecin-class drugs bound to their target have been essential in guiding this design work, because they reveal which parts of the molecule are critical for trapping topoisomerase I and which parts can be modified to attach linkers, improve solubility, or tweak potency.17Journal of Medicinal Chemistry. Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase I−DNA Covalent Complex
Where the Drug Accumulates in the Tree
For anyone trying to harvest camptothecin from actual trees, a practical question looms: which part of the tree has the most? The answer depends on the age of the tissue. Plantations established in Louisiana found that after one year of growth, all plant parts contained camptothecins, but bark consistently had higher concentrations than wood, and branches, roots, and stems accumulated more than leaves. Dried shoots contained about 0.042% camptothecin, while dried roots came in slightly higher at about 0.051%.18Canadian Journal of Botany. Camptothecin yield and distribution within Camptotheca acuminata trees cultivated in Louisiana
A separate finding complicates the picture in an encouraging way. Young leaves turn out to accumulate camptothecin at roughly 0.4% of their dry weight, which is about 1.5 times the concentration found in seeds and 2.5 times that in bark. As the leaves mature, the concentration drops rapidly.19PubMed. Sites of accumulation of the antitumor alkaloid camptothecin in Camptotheca acuminata This matters because harvesting young leaves does not kill the tree, unlike stripping bark or digging up roots. If commercial production could focus on leaf harvest from managed plantations, it might reduce pressure on wild populations while being more sustainable in the long run.
Fungi That Make Camptothecin Without the Tree
One of the more surprising discoveries in this field is that you do not necessarily need the tree at all. Endophytic fungi, microorganisms that live inside plant tissues without causing disease, have been isolated from Camptotheca acuminata that can produce camptothecin on their own. In one study, 94 endophytic fungal strains were isolated from the tree’s tissues, and 16 of them showed toxic effects on cancer cells. A strain identified as Fusarium solani was confirmed to produce camptothecin and displayed impressive activity against cancer cell lines.20PubMed Central. Characterization and antitumor activity of camptothecin from endophytic fungus Fusarium solani isolated from Camptotheca acuminate Other research groups have independently confirmed fungal camptothecin production using different endophytic species isolated from the tree’s inner bark under standard fermentation conditions.21PubMed. An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues
The practical appeal is obvious: growing fungi in fermentation tanks is far faster and more controllable than cultivating trees. But the yields from fungal cultures have so far remained much lower than those from plant tissue, and the production levels tend to decline over successive generations of the fungi in culture. This remains an active area of research rather than a commercially viable alternative, at least for now.
How the Tree Makes Camptothecin
The biosynthetic pathway that Camptotheca acuminata uses to build camptothecin is long and complex, involving a chain of chemical transformations that starts from simple building blocks and ends with a molecule intricate enough to trap a human enzyme on DNA. A chromosome-level genome assembly of the tree revealed that its pathway shares early steps with the pathway used by the Madagascar periwinkle (Catharanthus roseus, source of the anticancer drugs vincristine and vinblastine). Both trees build the same intermediate molecules using similar enzymes. But after a compound called loganic acid, the pathways diverge sharply. The periwinkle converts loganic acid through loganin and then secologanin, while Camptotheca acuminata converts it directly to secologanic acid and then to strictosidinic acid, a critical branch point unique to its camptothecin-producing route.22Nature Communications. A chromosome-level Camptotheca acuminata genome assembly provides insights into the evolutionary origin of camptothecin biosynthesis
Understanding this divergence has practical implications. If you want to produce camptothecin or its precursors in microorganisms through metabolic engineering, you need to know exactly which enzymatic steps to transplant. Recent work in engineered yeast has achieved production of strictosidinic acid, a key intermediate, from simple feedstocks like glucose and tryptophan. After rounds of optimization, researchers reached titers of roughly 548 mg/L of strictosidinic acid in fed-batch cultivation.23Journal of Biotechnology. Production of the anticancer drug intermediate strictosidinic acid in engineered yeast That is still a long way from a complete microbial synthesis of camptothecin itself, but it represents real progress toward a supply chain that does not depend on trees or tree-derived fungi.
Fighting Parasites, Not Just Cancer
Cancer is not the only disease where camptothecin’s mechanism turns out to be useful. The parasites that cause sleeping sickness, Chagas disease, and leishmaniasis also rely on topoisomerase I to manage their DNA. When these organisms are exposed to camptothecin, their nuclear and mitochondrial DNA gets cleaved and trapped with protein, just as happens in cancer cells. The drug kills Trypanosoma brucei and Trypanosoma cruzi at low concentrations, with Leishmania donovani requiring slightly more.24PubMed. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania These tropical diseases collectively affect millions of people and have limited treatment options, so camptothecin represents a lead compound for developing new antiparasitic drugs. The broader picture of camptothecin’s biological activity beyond cancer has been expanding steadily.25PubMed Central. Perspectives on biologically active camptothecin derivatives
Conservation Under Pressure
There is an uncomfortable tension built into the Camptotheca acuminata story. The tree that produces one of humanity’s most valuable anticancer compounds is itself under threat. Wild populations in China have been shrinking due to habitat loss and overharvesting, and the species is now the subject of conservation and management efforts focused on understanding which ecological factors shape its remaining distribution.1PubMed Central. Insight into the Influence of Ecological Factors on Shaping Distribution Patterns of Camptotheca acuminata for Conservation and Management Experimental cultivation outside China has been attempted, but the germplasm base is so narrow that these plantations represent a genetic bottleneck, making the cultivated population vulnerable to disease or environmental shifts.2HortScience. Micropropagation of Camptotheca acuminata
This is ultimately why the parallel tracks of research into fungal production, yeast-based synthesis, and chemical synthesis matter so much. If the pharmaceutical supply of camptothecin-derived drugs can be decoupled from wild or plantation-grown trees, it eases one of the major pressures on the species. The young-leaf harvesting approach offers a middle path: it allows tree-based production without killing the source organism, but it still requires large-scale cultivation. For a species with limited genetic diversity, even sustainable harvesting carries risks if the planted population is too genetically uniform to withstand a pathogen outbreak or climate shift. The long-term security of the camptothecin drug supply likely depends on multiple production methods running in parallel rather than any single approach.